Browse by Journal Title

2023

Clinical implications and dynamics of clonal hematopoiesis in anti-CD19 CAR T-cell treated patients.
Panagiota, V., Kerschbaum, J.F., Penack, O., Stein, C.M., Arends, C.M., Koenecke, C., Strzelecka, P.M., Kloos, A., Wiegand, L., Lasch, A., Altwasser, R., Halik, A., Gabdoulline, R., Thomson, J., Weibl, K., Franke, G.N., Berger, C., Hasenkamp, J., Ayuk, F., Na, I.K., Beutel, G., Keller, U., Bullinger, L., Wulf, G.G., Kröger, N., Vucinic, V., Heuser, M. and Damm, F.
HemaSphere 7 (10): e957. October 2023

Inferior outcomes of EU versus US patients treated with CD19 CAR-T for relapsed/refractory large B-cell lymphoma: association with differences in tumor burden, systemic inflammation, bridging therapy utilization, and CAR-T product use.
Bücklein, V., Perez, A., Rejeski, K., Iacoboni, G., Jurinovic, V., Holtick, U., Penack, O., Kharboutli, S., Blumenberg, V., Ackermann, J., Frölich, L., Johnson, G., Patel, K., Arciola, B., Mhaskar, R., Wood, A., Schmidt, C., Albanyan, O., Gödel, P., Hoster, E., Bullinger, L., Mackensen, A., Locke, F., von Bergwelt, M., Barba, P., Subklewe, M. and Jain, M.D.
HemaSphere 7 (8): e907. August 2023

2022

Genotype and intensive pretreatment influence outcome of acute myeloid leukemia patients treated with venetoclax in combination with hypomethylating agents or low-dose cytarabine: "real world" data from germany.
Braitsch, K., Schmalbrock, L.K., Jung, P., Bumeder, I., Kiewe, P., Hecker, J.S., Verbeek, M., Westermann, J., Bullinger, L., Keller, U., Bassermann, F., Krönke, J., Götze, K.S. and Rieger, K.
HemaSphere 6 (9): e759. September 2022

2021

The mTOR inhibitor temsirolimus added to rituximab combined with dexamethasone, cytarabine, and cisplatinum (R-DHAP) for the treatment of patients with relapsed or refractory DLBCL - results from the phase-II STORM trial.
Witzens-Harig, M., Viardot, A., Keller, U., Wosniok, J., Deuster, O., Klemmer, J., Geueke, A.M., Meißner, J., Ho, A.D., Atta, J., Marks, R., La Rosée, P., Buske, C., Dreyling, M.H. and Hess, G.
HemaSphere 5 (10): e636. October 2021

The EHA Research Roadmap: Malignant Myeloid Diseases.
Döhner, H., Malcovati, L., Ossenkoppele, G.J., Hochhaus, A., Maria Vannucchi, A., Bullinger, L., Cervantes, F., Craddock, C., de Witte, T., Döhner, K., Dombret, H., Fenaux, P., Geissler, J., Germing, U., Guilhot, F., Harrison, C., Hellström-Lindberg, E., Passamonti, F., Sierra, J., Skoda, R. and Wierzbowska, A.
HemaSphere 5 (9): e635. September 2021

NEMHESYS - European perspective on the implementation of next-generation sequencing into clinical diagnostics.
Serramito-Gómez, I., Clarke, K.M., Rodríguez-Vicente, A.E., McGimpsey, J.E., Abáigar, M., Díez, C.B., Benito, R., Bullinger, L., Mills, K.I. and Hernández Rivas, J.M.
HemaSphere 5 (3): e541. March 2021

Gene expression profiling predicts sensitivity of chronic lymphocytic leukemia cells to dasatinib.
Blätte, T.J., Machnicki, M.M., Glodkowska-Mrowka, E., Dolnik, A., Karp, M., Karczmarczyk, A., Giannopoulos, K., Bullinger, L. and Stoklosa, T.
HemaSphere 5 (1): e514. January 2021

2020

Final results of a phase I/II trial of the combination Bendamustine and Rituximab with Temsirolimus (BeRT) in relapsed mantle cell lymphoma and follicular lymphoma.
Hess, G., Wagner, K., Keller, U., La Rosee, P., Atta, J., Hübel, K., Lerchenmueller, C., Schoendube, D., Witzens-Harig, M., Ruckes, C., Medler, C., van Oordt, C., Klapper, W., Theobald, M. and Dreyling, M.
HemaSphere 4 (3): e398. June 2020